Gold prices bounce off 3-week lows; demand likely longer term
In a recent filing with the Securities and Exchange Commission, Richard Glaze, the Chief Information Officer at CONMED Corp (NYSE:CNMD), reported a sale of common stock valued at $16,796. The transaction, dated February 11, involved the sale of 257 shares at a price of $65.3542 per share. Following this sale, Glaze no longer holds any shares in the company. The medical technology company, currently valued at $1.96 billion, is trading near its 52-week low with a P/E ratio of 14.8. According to InvestingPro analysis, CNMD appears undervalued, with a strong financial health score and a 13-year track record of consistent dividend payments. Discover more insights and 6 additional ProTips for CNMD with an InvestingPro subscription, including detailed valuation metrics and growth forecasts in our comprehensive Pro Research Report.
In other recent news, CONMED Corporation has been the subject of several analyst actions following its announcement of fourth-quarter 2024 earnings and 2025 guidance. Needham reduced its price target for CONMED from $97.00 to $91.00, maintaining a Buy rating despite lower-than-expected 2025 guidance due to ongoing supply chain challenges. JPMorgan, on the other hand, downgraded CONMED from Overweight to Neutral and lowered its price target to $70.00, citing concerns over the company’s lower-than-anticipated earnings guidance for 2025.
Stifel maintained its Buy rating and $72.00 price target for CONMED, following an analysis of the company’s Airseal system, which showed continued growth and positive outlook despite competition. The analysis revealed a year-over-year growth in non-robotic Airseal consumables, indicating successful commercialization efforts outside of robotic applications.
In addition to analyst actions, CONMED announced a quarterly cash dividend of $0.20 per share for shareholders of record as of December 20, 2024, payable on January 3, 2025. This recent development demonstrates the company’s commitment to returning value to its shareholders. Despite varying views from analysts, these recent events provide investors with a comprehensive perspective on CONMED’s financial performance and future outlook.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.